Xiamen Amoytop Biotech Co., Ltd. is an innovative biopharmaceutical company in China, specialized in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for major diseases (such as viral hepatitis, malignant tumors) and immunotherapy. Currently, Amoytop Biotech is specially focusing on CHB (chronic hepatitis B) treatment aiming to achieve breakthroughs in clinical cure of CHB.

Targeting major diseases and immunotherapy fields, Amoytop Biotech has built an innovation platform covering the expression, long-acting modification and industrialization of various protein drugs, and owned the innovation ability in fundamental research, pilot-scale research, clinical study and industrialization research. Now,and been awarded as a national innovation-oriented enterprise which has advantages in national intellectual property. Keeping the global market in mind, Amoytop Biotech spares every effort to explore international markets based on the domestic market. Up to now, Amoytop Biotech has marketed its products in South-East Asia, South America and CIS area. Through technical innovation, scientific management and product industrialization, Amoytop Biotech aims to gradually become a leading international biopharmaceutical company in China.